Literature DB >> 33563994

Programmable human histone phosphorylation and gene activation using a CRISPR/Cas9-based chromatin kinase.

Jing Li1, Barun Mahata1, Mario Escobar2, Jacob Goell1, Kaiyuan Wang1, Pranav Khemka1, Isaac B Hilton3,4.   

Abstract

Histone phosphorylation is a ubiquitous post-translational modification that allows eukaryotic cells to rapidly respond to environmental stimuli. Despite correlative evidence linking histone phosphorylation to changes in gene expression, establishing the causal role of this key epigenomic modification at diverse loci within native chromatin has been hampered by a lack of technologies enabling robust, locus-specific deposition of endogenous histone phosphorylation. To address this technological gap, here we build a programmable chromatin kinase, called dCas9-dMSK1, by directly fusing nuclease-null CRISPR/Cas9 to a hyperactive, truncated variant of the human MSK1 histone kinase. Targeting dCas9-dMSK1 to human promoters results in increased target histone phosphorylation and gene activation and demonstrates that hyperphosphorylation of histone H3 serine 28 (H3S28ph) in particular plays a causal role in the transactivation of human promoters. In addition, we uncover mediators of resistance to the BRAF V600E inhibitor PLX-4720 in human melanoma cells using genome-scale screening with dCas9-dMSK1. Collectively, our findings enable a facile way to reshape human chromatin using CRISPR/Cas9-based epigenome editing and further define the causal link between histone phosphorylation and human gene activation.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33563994      PMCID: PMC7873277          DOI: 10.1038/s41467-021-21188-2

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  44 in total

Review 1.  Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.

Authors:  Inna V Fedorenko; Kim H T Paraiso; Keiran S M Smalley
Journal:  Biochem Pharmacol       Date:  2011-05-25       Impact factor: 5.858

Review 2.  Chromatin modifications and their function.

Authors:  Tony Kouzarides
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

3.  Chromatin Kinases Act on Transcription Factors and Histone Tails in Regulation of Inducible Transcription.

Authors:  Steven Z Josefowicz; Miho Shimada; Anja Armache; Charles H Li; Rand M Miller; Shu Lin; Aerin Yang; Brian D Dill; Henrik Molina; Hee-Sung Park; Benjamin A Garcia; Jack Taunton; Robert G Roeder; C David Allis
Journal:  Mol Cell       Date:  2016-10-20       Impact factor: 17.970

4.  MSK1 activity is controlled by multiple phosphorylation sites.

Authors:  Claire E McCoy; David G Campbell; Maria Deak; Graham B Bloomberg; J Simon C Arthur
Journal:  Biochem J       Date:  2005-04-15       Impact factor: 3.857

5.  A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.

Authors:  Martin Jinek; Krzysztof Chylinski; Ines Fonfara; Michael Hauer; Jennifer A Doudna; Emmanuelle Charpentier
Journal:  Science       Date:  2012-06-28       Impact factor: 47.728

6.  Functional annotation of native enhancers with a Cas9-histone demethylase fusion.

Authors:  Nicola A Kearns; Hannah Pham; Barbara Tabak; Ryan M Genga; Noah J Silverstein; Manuel Garber; René Maehr
Journal:  Nat Methods       Date:  2015-03-16       Impact factor: 28.547

7.  Protein kinase Msk1 physically and functionally interacts with the KMT2A/MLL1 methyltransferase complex and contributes to the regulation of multiple target genes.

Authors:  Maaike Wiersma; Marianne Bussiere; John A Halsall; Nil Turan; Robert Slany; Bryan M Turner; Karl P Nightingale
Journal:  Epigenetics Chromatin       Date:  2016-11-11       Impact factor: 4.954

8.  Mitogen-induced distinct epialleles are phosphorylated at either H3S10 or H3S28, depending on H3K27 acetylation.

Authors:  Dilshad H Khan; Shannon Healy; Shihua He; Daniel Lichtensztejn; Ludger Klewes; Kiran L Sharma; Veronica Lau; Sabine Mai; Geneviève P Delcuve; James R Davie
Journal:  Mol Biol Cell       Date:  2017-01-11       Impact factor: 4.138

Review 9.  The molecular hallmarks of epigenetic control.

Authors:  C David Allis; Thomas Jenuwein
Journal:  Nat Rev Genet       Date:  2016-06-27       Impact factor: 53.242

10.  dCas9-based epigenome editing suggests acquisition of histone methylation is not sufficient for target gene repression.

Authors:  Henriette O'Geen; Chonghua Ren; Charles M Nicolet; Andrew A Perez; Julian Halmai; Victoria M Le; Joel P Mackay; Peggy J Farnham; David J Segal
Journal:  Nucleic Acids Res       Date:  2017-09-29       Impact factor: 19.160

View more
  9 in total

Review 1.  Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies.

Authors:  Kelsie L Becklin; Garrett M Draper; Rebecca A Madden; Mitchell G Kluesner; Tomoyuki Koga; Miller Huang; William A Weiss; Logan G Spector; David A Largaespada; Branden S Moriarity; Beau R Webber
Journal:  CRISPR J       Date:  2022-08

Review 2.  Is There a Histone Code for Cellular Quiescence?

Authors:  Kenya Bonitto; Kirthana Sarathy; Kaiser Atai; Mithun Mitra; Hilary A Coller
Journal:  Front Cell Dev Biol       Date:  2021-10-29

Review 3.  Engineering the next generation of cell-based therapeutics.

Authors:  Caleb J Bashor; Isaac B Hilton; Hozefa Bandukwala; Devyn M Smith; Omid Veiseh
Journal:  Nat Rev Drug Discov       Date:  2022-05-30       Impact factor: 112.288

4.  Interrogation of the dynamic properties of higher-order heterochromatin using CRISPR-dCas9.

Authors:  Yuchen Gao; Mengting Han; Stephen Shang; Haifeng Wang; Lei S Qi
Journal:  Mol Cell       Date:  2021-08-23       Impact factor: 19.328

5.  MSK-Mediated Phosphorylation of Histone H3 Ser28 Couples MAPK Signalling with Early Gene Induction and Cardiac Hypertrophy.

Authors:  Emma L Robinson; Faye M Drawnel; Saher Mehdi; Caroline R Archer; Wei Liu; Hanneke Okkenhaug; Kanar Alkass; Jan Magnus Aronsen; Chandan K Nagaraju; Ivar Sjaastad; Karin R Sipido; Olaf Bergmann; J Simon C Arthur; Xin Wang; H Llewelyn Roderick
Journal:  Cells       Date:  2022-02-09       Impact factor: 6.600

6.  Silencing FYVE, RhoGEF, and PH domain containing 1 (FGD1) suppresses melanoma progression by inhibiting PI3K/AKT signaling pathway.

Authors:  Zehao Niu; Yan Li; Yujian Xu; Weiqian Jiang; Ran Tao; Youbai Chen; Yan Han
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

7.  Systematic comparison of CRISPR-based transcriptional activators uncovers gene-regulatory features of enhancer-promoter interactions.

Authors:  Kaiyuan Wang; Mario Escobar; Jing Li; Barun Mahata; Jacob Goell; Spencer Shah; Madeleine Cluck; Isaac B Hilton
Journal:  Nucleic Acids Res       Date:  2022-08-12       Impact factor: 19.160

Review 8.  Reversing Post-Infectious Epigenetic-Mediated Immune Suppression.

Authors:  Carlos O Ontiveros; Rosa S Guerra-Resendez; Tomoki Nishiguchi; Malik Ladki; Isaac B Hilton; Larry S Schlesinger; Andrew R DiNardo
Journal:  Front Immunol       Date:  2021-06-07       Impact factor: 8.786

Review 9.  Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing.

Authors:  Eric Alves; Shahama Taifour; Riccardo Dolcetti; Jonathan Chee; Anna K Nowak; Silvana Gaudieri; Pilar Blancafort
Journal:  Mol Ther Methods Clin Dev       Date:  2021-04-24       Impact factor: 6.698

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.